수용체 ≫ GPCR ≫ 독과약 ≫ Shape

drug design(형태,용해도)

drug design : 독과약
- 신약 개발 확률
- GPCR 역할 : 신약 개발의 돌파구 : 약물 작용의 절반
- 약의 분자형태 QSAR
- 고아 GPCR



- 분자량 :
- 용해도 :

1. Natural Products: MW ~400-1000
   Structurally highly diverse,    Often biologically active
   Optimization process is time consuming,   High manufacturing costs

2. Synthetic compounds collections: M.W ~300-350.
  Drug-like,   Structural diversity is limited
  Optimization process straightforward,   Low manufacturing costs

3. Peptoids, peptides and peptidomimetics derived from a target protein : M.W >600
  Fast assembly through linear assembly of similar·building blocks
  Limited,“rather flexible” diversity.
   Usually not “drug-like”,  Optimization process often long and tedious

4. Small-molecular-weight compound libraries from combinatorial and parallel chemistry: Molecular weight <600.
  Fast and convergent assembly using reactive building blocks
  Limited chemica1and structural diversity
  “Drug-like”,   Fast optimization process,  Low manufactoring costs